Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Our current portfolio includes three late-stage product candidates, Cimzia (certolizumab pegol), for the treatment of moderate to severe plaque psoriasis, DRM04, for the treatment of hyperhidrosis, or excessive sweating and DRM01, a topical sebum inhibitor for acne.
Company Growth (employees)
Menlo Park, US
Size (employees)
95 (est)+54%
Dermira was founded in 2011 and is headquartered in Menlo Park, US

Key People at Dermira

Thomas G. Wiggans

Thomas G. Wiggans

Co-Founder & CEO
Kin Chan

Kin Chan

Vice President of Engineering
Janice Drew

Janice Drew

Vice President & Project Management
Eugene A. Bauer

Eugene A. Bauer

Founder & Chief Medical Officer
Hans Hofland

Hans Hofland

Vice President ofResearch
Chris Griffith

Chris Griffith

Founder & Vice President, Corporate Development & Strategy

Dermira Office Locations

Dermira has an office in Menlo Park
Menlo Park, US (HQ)
150 275 Middlefield Rd

Dermira Metrics

Dermira Financial Metrics

Revenue (2016)

$22.6 m

Revenue growth (2015-16), %


Net income (2016)

($89.1 m)

Market capitalization (21-Mar-2017)

$1.2 b

Closing share price (21-Mar-2017)

Dermira's current market capitalization is $1.2 b.
Dermira's revenue was reported to be $22.6 m in FY, 2016 which is a 209.4% increase from the previous period.
FY, 2014FY, 2015FY, 2016


$7.3 m$22.6 m

Revenue growth, %


Operating expense total

$39 m$86.9 m


($31.7 m)($79.6 m)

EBIT margin, %


Net Income

($31.9 m)($78.4 m)($89.1 m)
FY, 2014FY, 2015

Cash From Operating Activities

$33.2 m$51.9 m

Dermira Market Value History

Dermira Company Life

You may also be interested in